Gilead Sciences (NASDAQ:GILD) PT Lowered to $75.00

Gilead Sciences (NASDAQ:GILD) had its target price lowered by equities research analysts at UBS Group from $81.00 to $75.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price target would suggest a potential upside of 13.36% from the company’s previous close.

A number of other analysts have also recently commented on GILD. Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Wells Fargo & Company lowered their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Finally, Oppenheimer lowered their target price on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $66.16 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences has a 1 year low of $65.90 and a 1 year high of $87.86. The company has a market cap of $82.37 billion, a PE ratio of 14.70, a PEG ratio of 0.92 and a beta of 0.19. The company’s 50-day moving average is $72.10 and its two-hundred day moving average is $76.58.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $1.67 earnings per share. Equities analysts anticipate that Gilead Sciences will post 6.55 earnings per share for the current year.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in the business. Capital Advisors Ltd. LLC increased its position in shares of Gilead Sciences by 12.9% in the first quarter. Capital Advisors Ltd. LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 162 shares during the period. Exchange Capital Management Inc. increased its position in shares of Gilead Sciences by 0.9% in the first quarter. Exchange Capital Management Inc. now owns 37,440 shares of the biopharmaceutical company’s stock worth $2,742,000 after purchasing an additional 350 shares during the period. Synergy Asset Management LLC bought a new position in shares of Gilead Sciences in the first quarter worth $3,724,000. Cullinan Associates Inc. increased its position in shares of Gilead Sciences by 17.3% in the first quarter. Cullinan Associates Inc. now owns 139,288 shares of the biopharmaceutical company’s stock worth $10,203,000 after purchasing an additional 20,532 shares during the period. Finally, Iams Wealth Management LLC increased its position in shares of Gilead Sciences by 0.8% in the first quarter. Iams Wealth Management LLC now owns 20,609 shares of the biopharmaceutical company’s stock worth $1,498,000 after purchasing an additional 167 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.